Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 6, 2026

Top Research Reports for Procter & Gamble, American Express & TJX

View original at finance.yahoo.com
Top Research Reports for Procter & Gamble, American Express & TJX Friday, March 6, 2026 The Zacks Research Daily presents the best research output of our analyst team…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Genie Energy's retail unit (GRE) is expanding a resilient electricity customer base by targeting high-consumption meters and improving churn

    80% confidence

  • Procter & Gamble is facing mounting margin pressure from elevated commodity costs, rising tariffs and higher financing expenses

    80% confidence

  • CompX Marine Components operating income skyrocketed 205%, gross margin hit 30.5% and operating margin was 21% for first nine months of 2025

    80% confidence

  • PG's resilient performance underscores the power of its brand portfolio and disciplined operating strategy

    80% confidence

  • Procter & Gamble continues to generate steady organic sales, supported by pricing strength and broad-based category growth, particularly in Beauty, Health Care and Grooming

    80% confidence

  • American Express is benefiting from strong spending growth, particularly from Millennials and Gen Z, supported by experience-driven rewards, travel and dining platforms and expanding digital capabilities

    80% confidence

  • Genie Energy margin rebound expected after low-margin municipal aggregation contracts expire in the fourth quarter of 2025

    80% confidence

  • A $400 million tariff headwind and a $250 million drag from higher interest and taxes threaten earnings growth at Procter & Gamble

    80% confidence

  • Woodward's Aerospace segment revenues expected to grow 15-20% in fiscal 2026

    80% confidence

  • American Express rising expense intensity, elevated credit-loss provisions amid weakening consumer credit trends and relatively high leverage could pressure margins and earnings stability

    80% confidence

  • Coterra plans to spend $2.25 billion in capital expenditures in 2026

    80% confidence

  • TJX continues to benefit from its resilient off-price model, strong value proposition and steady demand across apparel and home categories

    80% confidence

  • TJX sees long-term growth opportunities through global store expansion and disciplined execution across its retail banners

    80% confidence

  • Diversegy's advisory model is scaling profitably and could double operating profit in 2026

    80% confidence

Data points we hold from this source

Procter & Gamble · interest tax drag250 million_USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Top Research Reports for Procter & Gamble, American Express & TJX — Source | Via News | Finance Via News